Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04574414
Other study ID # KE_24042019A
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date October 1, 2020
Est. completion date December 31, 2023

Study information

Verified date September 2020
Source Jagiellonian University
Contact Marcin Szwed, Dr. hab.
Phone 12 663 24 40
Email m.szwed@uj.edu.pl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

- Background: Recent studies have linked exposure to airborne particulate matter (PM) to neurodevelopmental outcomes but the findings are mixed and mechanisms are unclear. We aim to determine the impact of PM on the developing brain of schoolchildren in Poland, a European country characterized by very high levels of air pollution. The investigators aim to determine the impact of PM on the developing brain of schoolchildren in Poland, a European country characterized by very high levels of air pollution.

- Study area: 19 towns in three voivodeships (Lesser Poland, Silesian, Opole) in the southern Poland. To reduce confounding by urbanicity and at the same time, to achieve sufficient contrasts in PM levels without too high logistic costs, towns were selected by size (big and small) and by PM levels (high, medium and low).

- Design: Case-control study with 800 children recruited over two school years, with two population controls per one ADHD case. Suspected cases will be recruited in specialized facilities and presumably ADHD-free children will be recruited in primary schools.

- Exposure assessment: Poland-wide PM and other air pollutants' grids will be created for the years 2006 to 2021 using statistical models to incorporate land use data, estimates from transport models, satellite observations and air pollution measurements from Polish monitoring network. Prenatal, early-life, lifelong and concurrent exposures will be calculated.

- Psychological testing: Every child and their parents will complete a series of psychological tests and interviews that will be conducted during their three visits to the recruitment facility.

- Neuroimaging: Each participant will undergo a Magnetic Resonance Imaging (MRI) scanning session that will be performed accordingly to the Human Connectome Adolescent Brain Cognitive Development project recommendations. Scanning will be performed on a single scanner in Krakow.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 800
Est. completion date December 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 10 Years to 13 Years
Eligibility Inclusion Criteria:

- Attending school in one of the specified towns

- Age 10-13 years (4th-6th grade)

- Native Polish speaker

- Normal or above intelligence

- Standard educational opportunities

- Normal or corrected to normal visual and auditory acuity

- No gross sensory deficit, no gross behavioural problems

- No history of neurological disease

Exclusion Criteria:

- Autism spectrum disorder (ASD)

- FAS

- FAE

- Intellectual disability

- Metabolic disorders

- Genetic disorders

- Epilepsy

- Cerebral palsy

- Mood disorders

- Tourette Syndrome

- Other illnesses including pharmacotherapy

- Apgar score < 8

- Low birth weight (below 2500 g)

- Preterm birth (below 35th weeks of gestation)

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Psychological testing and MRI imaging
Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD. Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI.

Locations

Country Name City State
Poland Institute of Psychology Kraków

Sponsors (3)

Lead Sponsor Collaborator
Jagiellonian University Foundation for Polish Science, Institute of Environmental Protection - National Research Institute (IOS-PIB)

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Attention Deficit Hyperactivity Disorder (ADHD) ADHD and comorbidities will be assessed by Conners 3 questionnaire October 1, 2020 until December 31, 2022
Primary Cognitive functioning Memory, attention, and executive functions measurement will be assessed by Diagnostic battery for cognitive functions evaluation (PU1) October 1, 2020 until December 31, 2022
Primary Attention control Attention Network Test (ANT) will be used. October 1, 2020 until December 31, 2022
Primary Sustained and selective attention Computer Conners Continuous Performance Task (CPT) will be used. October 1, 2020 until December 31, 2022
Primary Inhibition control Conditioned Approach Response Inhibition Task (CARIT) will be used as part of MRI measurements. October 1, 2020 until December 31, 2022
Primary Inhibition control Go/No Go task will be used as part of MRI measurements. October 1, 2020 until December 31, 2022
Secondary Full-Scale Intelligence Quotient (IQ) IQ will be measured by Stanford-Binet Intelligence Scales, 5th Edition (SB5). October 1, 2020 until December 31, 2022
Secondary Family functioning Polish adaptation of the FACES-IV (Flexibility and Cohesion Evaluation Scales; SOR) will be used to estimate social functioning of the children (family functioning). October 1, 2020 until December 31, 2022
Secondary Relationships with siblings Siblings Relationship Questionnaire (KRR), which is a supplement for the SOR Scale will be used to assess social functioning of the children (relationships with siblings). October 1, 2020 until December 31, 2022
Secondary Behavioural, emotional, and social problems Youth Self-Report Scale (YSR) will be used for this assessment. October 1, 2020 until December 31, 2022
Secondary Behavioural problems Child Behaviour Checklist (CBCL) questionnaire will collect information on the eight syndrome domains: anxious/depressed, depressed, somatic complaints, social problems, thought problems, attention problems, rule-breaking behaviour, aggressive behaviour October 1, 2020 until December 31, 2022
See also
  Status Clinical Trial Phase
Recruiting NCT06129396 - Effects of Aerobic Exercise Intervention in Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) N/A
Completed NCT04779333 - Lifestyle Enhancement for ADHD Program 2 N/A
Recruiting NCT05935722 - Evaluation of a Home-based Parenting Support Program: Parenting Young Children N/A
Completed NCT03148782 - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase N/A
Completed NCT04832737 - Strength-based Treatment Approach for Adults With ADHD N/A
Recruiting NCT04631042 - Developing Brain, Impulsivity and Compulsivity
Recruiting NCT05048043 - Development of a Game-supported Intervention N/A
Completed NCT03337646 - Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism Phase 4
Not yet recruiting NCT06454604 - Virtual Reality Treatment for Emerging Adults With ADHD Phase 2
Not yet recruiting NCT06080373 - Formulation-based CBT for Adult Inmates With ADHD: A Randomized Controlled Trial N/A
Not yet recruiting NCT06406309 - Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD N/A
Completed NCT02477280 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance Phase 4
Completed NCT02911194 - a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT02780102 - Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD N/A
Completed NCT02829970 - Helping College Students With ADHD Lead Healthier Lifestyles N/A
Completed NCT02390791 - New Technologies to Help Manage ADHD N/A
Completed NCT02473185 - Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest Phase 4
Completed NCT02555150 - A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD Phase 3
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Recruiting NCT04175028 - Neuromodulation of Executive Function in the ADHD Brain N/A